<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646995</url>
  </required_header>
  <id_info>
    <org_study_id>14.18.CLI</org_study_id>
    <nct_id>NCT02646995</nct_id>
  </id_info>
  <brief_title>Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate if the use of a newly developed lipid formulation
      versus fish oil would better enable the absorption of essential fatty acids after 12 weeks of
      supplementation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of accretion in erythrocytes of eicosapentanoic acid (EPA) between the 2 groups from Baseline to V3 (12 weeks of treatment), as determined by gas chromatography</measure>
    <time_frame>From Baseline till 12 weeks of treatment (V3)</time_frame>
    <description>determine the accretion in erythrocytes of EPA derived from the modified lipd formulation as compared to EPA from fish oil between the 2 groups after 12 weeks of supplementation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified lipid formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fish oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>modified lipid formulation</intervention_name>
    <description>Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <description>Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously diagnosed CF according to established criteria (diagnosis of CF will be
             based on either two positive sweat chloride tests of &gt;60 mEq/L or the identification
             of two detectable mutations associated with CF)

          2. Exocrine pancreatic insufficiency defined by pathological fecal elastase (&lt;15µg/g)
             found in the Medical History of the patient

          3. Informed consent letter signed and dated by their parents or legal guardians before
             inclusion in the study, and assent signed and dated by the child if he or she is ≥ 14
             years old

        Exclusion Criteria:

          1. Any change (initiation, change in type of drug, dose modification, schedule
             modification, interruption, discontinuation, or re-initiation) in a chronic
             treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior
             to baseline

          2. Exposure to another investigational drug or dietary supplements and enteral nutrition
             containing EPA and docosahexaenoic acid (DHA), Fish or the use of any other supplement
             containing fish oil within 4 weeks prior to baseline.

          3. Treatment with intravenous antibiotics within 4 weeks prior to baseline

          4. Newly started oral antibiotic treatment within 4 weeks prior to Baseline

          5. History of solid organ or hematological transplantation

          6. Ongoing immunosuppressive therapy (other than corticosteroids) within 3 weeks prior to
             baseline

          7. Major complications of lung disease (including massive hemoptysis, pneumothorax, or
             pleural effusion) within 8 weeks prior to baseline

          8. Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection
             (including viral illnesses) within 3 weeks prior to baseline

          9. Having donated blood or had a transfusion of blood/blood products during the trial and
             3 months prior to screening or expected to do so during the study

         10. Any bleeding disorders at screening

         11. Patient who cannot be expected to comply with the study procedures.

         12. Currently participating or having participated in another clinical trial within 8
             weeks prior to baseline.

         13. Any known food allergy

         14. Incapacity to swallow capsules
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gaudenz Hafen, MD</last_name>
    <phone>+41 (0) 21 314 84 70</phone>
    <email>gaudenz.hafen@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yann Kernen, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaudenz Hafen, MD</last_name>
      <phone>+41 (0) 21 314 84 70</phone>
      <email>gaudenz.hafen@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Yann Kernen, MD</last_name>
      <phone>+41 (0) 21 314 84 70</phone>
      <email>yann.kernen@chuv.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

